Quadrature Capital’s Cytek Biosciences CTKB Stock Holding History

Quadrature Capital’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$94.9K	Buy	+21,420	New	+$91.4K	﹤0.01%	1474
2025 Q2	–	Sell	-13,896	Closed	-$55.9K	–	1121
2025 Q1	$55.9K	Buy	+13,896	New	+$72K	﹤0.01%	971
2024 Q3	–	Sell	-21,229	Closed	-$118K	–	1031
2024 Q2	$118K	Buy	21,229 +5,969	+39%	+$35.9K	﹤0.01%	1019
2024 Q1	$102K	Buy	+15,260	New	+$121K	﹤0.01%	1130

Other funds holding CTKB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Quadrature Capital's CTKB Position: Q2 2026 in Review

Quadrature Capital opened a new position in Cytek Biosciences (CTKB) in Q2 2026: 21,420 shares worth $94.9K. The stake represents ﹤0.01% of the portfolio and ranks #1474 among its holdings. This is a return to the name: Quadrature Capital previously reported a position in CTKB as recently as Q1 2025.

Quadrature Capital first reported a position in CTKB in Q1 2024 and has held it in 4 quarters since. The position peaked at $118K in Q2 2024. 154 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

Quadrature Capital held 21,420 shares of Cytek Biosciences worth $94.9K as of Q2 2026.
Cytek Biosciences was a new Quadrature Capital position in Q2 2026.
Cytek Biosciences made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #1474 holding.
Quadrature Capital first reported a position in Cytek Biosciences in Q1 2024 and has held it in 4 quarters since.
Quadrature Capital's Cytek Biosciences position peaked at $118K in Q2 2024.
154 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.